The unexpected pandemic of 2020 costed the lives of thousands of people worldwide. Scientists still do not know the origin and cause of the virus, called the SARS-CoV-2 that causes COVID-19. Nonetheless, its mode of transmission is somewhat known. As such, our primary objective is not to deduce the origin but to procure an anti-virus that can at least curb the spread of the virus.
Therefore, scientists and health departments throughout the world have been working extensively, day and night, to develop such a cure. As such, the U.S department approved their efforts with the approval of related to the field recently.
On October 23, 2020, The U.S. Food and Drug Administration granted their complete approval for the drug remdesivir. The drug serves as an anti-viral drug and the treatment for the patients suffering from the COVID-19. The department established the subsequent conditional authorization for the drug back in May of 2020. Gilead Sciences, Inc., the California-based biopharmaceutical company, listed the drug as the only available treatment as of yet.
Consequently, after the announcement mentioned earlier, Gilead’s market shares on the New York Stock Exchange spiked a whole four per cent. Other countries such as Canada and most European countries have permitted temporary allowance for the use of the drug, remdesivir, as well.
Doctors primarily administer Remdesivir as an injection. Although the drug’s effectiveness is not yet confirmed, it shows comparatively good recovery in patients. For children aged 12 or above and weigh more significant than 40 kilograms, doctors can provide the drug in the approved quantity. Nevertheless, health departments can also administer medications such as steroid dexamethasone for treatment against COVID-19.
Official Statement: Remdesivir
The U.S. Food and Drug Administration publicised a statement following the granting of the approval of the remdesivir drug. They stated that the FDA committed themselves to look into the development and accessibility of various treatments of the COVID-19.
In this time of unanticipated emergency that risks public safety, the approval of the drug plays a vital role. Data from multiple clinical trials, after rigorous assessments, validate the license. The FDA hopes that this decision will prevent further spread and help cure currently affected patients.
Follow up on a similar article on Aurora Cannabis.